These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 11738306

  • 1. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery.
    Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD.
    J Am Coll Cardiol; 2001 Dec; 38(7):1994-2000. PubMed ID: 11738306
    [Abstract] [Full Text] [Related]

  • 2. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy--a meta analysis.
    Zeng Z, Wang F, Dou X, Zhang S, Pu J.
    Int J Cardiol; 2006 Sep 10; 112(1):80-4. PubMed ID: 16507323
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Clinical Effects between Percutaneous Transluminal Septal Myocardial Ablation and Modified Morrow Septal Myectomy on Patients with Hypertrophic Cardiomyopathy.
    Guo HC, Li JH, Jiang TY, Ren CW, Dai J, Zhou YJ, Lai YQ.
    Chin Med J (Engl); 2018 Mar 05; 131(5):527-531. PubMed ID: 29483385
    [Abstract] [Full Text] [Related]

  • 4. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Veselka J, Honek T.
    Int J Cardiol; 2003 Mar 05; 88(1):27-32. PubMed ID: 12659981
    [Abstract] [Full Text] [Related]

  • 5. [Long-term outcome of patients with hypertrophic obstructive cardiomyopathy post percutaneous transluminal septal ablation].
    Zheng SW, Shi HY, Dai JJ, Chen H, Wu WH, Qiu XB.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr 24; 48(4):294-301. PubMed ID: 32370480
    [Abstract] [Full Text] [Related]

  • 6. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets.
    van der Lee C, ten Cate FJ, Geleijnse ML, Kofflard MJ, Pedone C, van Herwerden LA, Biagini E, Vletter WB, Serruys PW.
    Circulation; 2005 Jul 26; 112(4):482-8. PubMed ID: 16027255
    [Abstract] [Full Text] [Related]

  • 7. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy.
    Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, Dolney DO, Blackstone EH.
    Ann Thorac Surg; 2008 Jan 26; 85(1):127-33. PubMed ID: 18154797
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
    Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S.
    J Am Coll Cardiol; 1998 Feb 26; 31(2):252-8. PubMed ID: 9462563
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography].
    Faber L, Seggewiss H, Fassbender D, Bogunovic N, Strick S, Schmidt HK, Gleichmann U.
    Z Kardiol; 1998 Mar 26; 87(3):191-201. PubMed ID: 9586154
    [Abstract] [Full Text] [Related]

  • 12. Percutaneous transluminal septal myocardial ablation: past, present, and future.
    Maekawa Y, Takamisawa I, Takano H, Takayama M.
    J Cardiol; 2022 Sep 26; 80(3):211-217. PubMed ID: 34924238
    [Abstract] [Full Text] [Related]

  • 13. Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients.
    Yao L, Li L, Lu XJ, Miao YL, Kang XN, Duan FJ.
    Cardiovasc Ultrasound; 2016 May 17; 14(1):18. PubMed ID: 27189485
    [Abstract] [Full Text] [Related]

  • 14. Latent outflow tract obstruction in hypertrophic cardiomyopathy: Clinical characteristics and outcomes of septal myectomy.
    Cui H, Schaff HV, Nishimura RA, Dearani JA, Geske JB, Ommen SR.
    J Thorac Cardiovasc Surg; 2022 Dec 17; 164(6):1863-1869.e1. PubMed ID: 33468328
    [Abstract] [Full Text] [Related]

  • 15. [Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy--results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing].
    Krejcí J, Groch L, Meluzín J, Vykypel T, Halámek J, Vitovec J.
    Vnitr Lek; 2006 Apr 17; 52(4):313-20. PubMed ID: 16755987
    [Abstract] [Full Text] [Related]

  • 16. Ameliorating the severity of sleep-disordered breathing concomitant with heart failure status after percutaneous transluminal septal myocardial ablation for drug-refractory hypertrophic obstructive cardiomyopathy.
    Akita K, Maekawa Y, Kohno T, Tsuruta H, Murata M, Fukuda K.
    Heart Vessels; 2017 Nov 17; 32(11):1320-1326. PubMed ID: 28555387
    [Abstract] [Full Text] [Related]

  • 17. Myocardial mechanical remodeling after septal myectomy for severe obstructive hypertrophic cardiomyopathy.
    Moravsky G, Bruchal-Garbicz B, Jamorski M, Ralph-Edwards A, Gruner C, Williams L, Woo A, Yang H, Laczay B, Rakowski H, Carasso S.
    J Am Soc Echocardiogr; 2013 Aug 17; 26(8):893-900. PubMed ID: 23800507
    [Abstract] [Full Text] [Related]

  • 18. Reverse remodeling after percutaneous transluminal septal myocardial ablation in severe but asymptomatic LVOT obstruction (RASTA) study: Rationale and design of transcatheter septal reduction in asymptomatic patients with severe hypertrophic obstructive cardiomyopathy.
    Arslan F, Akdim F, Ten Berg JM.
    Catheter Cardiovasc Interv; 2021 Feb 15; 97(3):488-492. PubMed ID: 32808736
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Real-world clinical outcomes of percutaneous transluminal septal myocardial ablation for patients with drug-refractory hypertrophic obstructive cardiomyopathy: results from a retrospective multicenter registry of non-high-volume centers.
    Nakamura K, Toba T, Otake H, Kakizaki S, Fujimoto D, Takahashi Y, Fukuyama Y, Kawamori H, Tanaka H, Takaya T, Iwasaki M, Kozuki A, Kawai H, Hayashi T, Shite J, Hirata KI.
    Heart Vessels; 2022 Nov 15; 37(11):1937-1946. PubMed ID: 35641828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.